-+ 0.00%
-+ 0.00%
-+ 0.00%

We Think You Can Look Beyond Genmab's (CPH:GMAB) Lackluster Earnings

Simply Wall St·11/15/2026 07:12:36
Listen to the news

Soft earnings didn't appear to concern Genmab A/S' (CPH:GMAB) shareholders over the last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

earnings-and-revenue-history
CPSE:GMAB Earnings and Revenue History November 15th 2026

How Do Unusual Items Influence Profit?

To properly understand Genmab's profit results, we need to consider the US$264m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Genmab doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Genmab's Profit Performance

Unusual items (expenses) detracted from Genmab's earnings over the last year, but we might see an improvement next year. Because of this, we think Genmab's earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at 31% per year over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For instance, we've identified 5 warning signs for Genmab (2 don't sit too well with us) you should be familiar with.

Today we've zoomed in on a single data point to better understand the nature of Genmab's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.